Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

43.65 

0.56 1.3%

as of Aug 16 '19

52 Week Range:

39.64 73.89


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids. The company offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. It also provides NARCAN for the emergency treatment of known or suspected opioid overdose; RSDL (Reactive Skin Decontamination Lotion Kit), a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard for intramuscular self-injection of atropine sulfate and obidoxime chloride. In addition, the company offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for treating botulinum disease; and VIGIV (vaccinia immune globulin intravenous) that addresses complications from smallpox vaccination. Further, it provides NuThrax, an anthrax vaccine; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; ADENOVIRUS 4/7, a live attenuated vaccine; rVSV-Lassa, a vaccine for prevention of Lassa fever; rVSV-Marburg, a vaccine for prevention of Marburg hemorrhagic fever; rVSV-Sudan, vaccine for prevention of Sudan hemorrhagic fever; rVSV-QUAD, a vaccine for prevention of hemorrhagic fever; and rVSV-Ebola, a vaccine for prevention of Ebola hemorrhagic fever. Additionally, the company offers FLU-IGIV to treat Influenza A infection in hospitalized patients; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract manufacturing services to third-party customers. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 6.66
7.82
10.55
10.59
12.30
12.76
13.61
15.36
13.50
13.43
18.88
growth rate 17.4% 34.9% 0.4% 16.2% 3.7% 6.7% 12.9% -12.1% -0.5% 40.6%
Earnings BIT 32.74
41.51
73.37
31.94
32.07
43.37
89.19
151.34
105.50
124.30
110.60
growth rate 26.8% 76.8% -56.5% 0.4% 35.2% 105.6% 69.7% -30.3% 17.8% -11.0%
Avg.PE 38.46
13.70
14.77
26.46
24.81
27.10
36.42
24.05
27.79
27.66
48.78
growth rate -64.4% 7.8% 79.2% -6.2% 9.2% 34.4% -34.0% 15.6% -0.5% 76.4%
ROA 7.33
9.80
12.24
4.40
4.23
5.23
4.67
6.32
5.14
8.10
3.80
growth rate 33.7% 24.9% -64.1% -3.9% 23.6% -10.7% 35.3% -18.7% 57.6% -53.1%
ROE 11.16
14.14
16.93
5.87
5.50
6.69
7.05
10.36
8.24
10.95
6.52
growth rate 26.7% 19.7% -65.3% -6.3% 21.6% 5.4% 47.0% -20.5% 32.9% -40.5%
ROIC 8.52
10.73
14.14
5.15
4.79
5.90
6.23
7.81
6.22
9.71
5.13
growth rate 25.9% 31.8% -63.6% -7.0% 23.2% 5.6% 25.4% -20.4% 56.1% -47.2%
Cur. Ratio 2.83
3.54
3.22
3.58
4.25
4.82
4.65
5.41
4.82
4.85
3.10
growth rate 25.1% -9.0% 11.2% 18.7% 13.4% -3.5% 16.3% -10.9% 0.6% -36.1%
Quick Ratio 2.34
3.11
2.89
3.23
3.84
4.33
3.67
4.42
3.97
3.24
1.91
growth rate 32.9% -7.1% 11.8% 18.9% 12.8% -15.2% 20.4% -10.2% -18.4% -41.1%
Leverage 1.46
1.43
1.35
1.32
1.28
1.28
1.71
1.58
1.63
1.17
2.21
growth rate -2.1% -5.6% -2.2% -3.0% 0.0% 33.6% -7.6% 3.2% -28.2% 88.9%
Balance Sheet Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 24.90
54.90
39.30
85.39
97.31
66.24
60.19
120.48
148.47
146.10
271.10
growth rate 120.5% -28.4% 117.3% 14.0% -31.9% -9.1% 100.2% 23.2% -1.6% 85.6%
Acct.Payable 62.58
55.63
53.48
40.93
37.97
34.65
41.80
80.70
growth rate -11.1% -3.9% -23.5% -7.2% -8.8% 20.6% 93.1%
Cur.Assets 152.90
193.80
243.50
254.42
263.35
273.12
432.18
537.41
510.22
485.40
620.80
growth rate 26.8% 25.6% 4.5% 3.5% 3.7% 58.2% 24.4% -5.1% -4.9% 27.9%
Total Assets 290.80
344.70
500.30
546.86
564.23
626.63
938.69
1,037.48
970.11
1,070.20
2,229.40
growth rate 18.5% 45.1% 9.3% 3.2% 11.1% 49.8% 10.5% -6.5% 10.3% 108.3%
Cash 91.50
102.90
169.00
144.12
141.67
179.34
280.50
308.30
271.51
178.30
112.20
growth rate 12.5% 64.2% -14.7% -1.7% 26.6% 56.4% 9.9% -11.9% -34.3% -37.1%
Inventory 18.30
13.50
12.70
14.66
15.16
14.64
65.67
60.89
74.00
142.80
205.80
growth rate -26.2% -5.9% 15.4% 3.4% -3.4% 348.5% -7.3% 21.5% 93.0% 44.1%
Cur.Liabilities 54.00
54.70
75.70
71.05
61.91
56.65
92.94
99.61
105.86
100.10
200.40
growth rate 1.3% 38.4% -6.1% -12.9% -8.5% 64.1% 7.2% 6.3% -5.4% 100.2%
Liabilities 91.40
103.50
130.90
132.62
122.87
137.01
385.49
377.47
373.91
157.90
1,218.50
growth rate 13.2% 26.5% 1.3% -7.4% 11.5% 181.4% -2.1% -0.9% -57.8% 671.7%
LT Debt 35.90
44.90
30.20
54.09
58.30
62.00
251.00
246.89
248.09
13.50
784.50
growth rate 25.1% -32.7% 79.1% 7.8% 6.3% 304.8% -1.6% 0.5% -94.6% 5,711.1%
Equity 199.30
241.20
369.50
414.25
441.36
489.62
553.20
660.02
596.21
912.30
1,010.90
growth rate 21.0% 53.2% 12.1% 6.5% 10.9% 13.0% 19.3% -9.7% 53.0% 10.8%
Common Shares 30.00
31.00
33.00
36.00
36.00
37.00
46.00
0.04
0.04
0.10
0.10
growth rate 3.3% 6.5% 9.1% 0.0% 2.8% 24.3% -99.9% 2.5% 143.9% 0.0%
Cash Flow Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 20.80
33.30
22.10
54.03
53.85
42.02
30.67
44.81
76.20
54.80
72.10
growth rate 60.1% -33.6% 144.5% -0.3% -22.0% -27.0% 46.1% 70.0% -28.1% 31.6%
Cash Dividends 0.00
0.00
0.00
0.00
0.00
45.00
45.00
45.00
growth rate 0.0% 0.0%
Cash From OA 7.30
30.50
98.00
12.19
39.64
96.97
112.32
42.52
54.60
208.10
41.80
growth rate 317.8% 221.3% -87.6% 225.3% 144.6% 15.8% -62.2% 28.4% 281.1% -79.9%
FCF per Share -0.44
-0.09
2.38
-1.19
-0.39
0.05
1.24
0.83
-0.03
1.05
4.33
growth rate 0.0% 100.0% -100.0% 0.0% 100.0% 2,380.0% -33.1% -100.0% 100.0% 312.4%
Sale Purchase of Stock 10.03
-5.15
6.64
14.08
25.96
17.13
19.35
growth rate -100.0% 100.0% 112.2% 84.4% -34.0% 13.0%
FCF -13.00
-3.00
77.00
-39.00
-14.00
55.00
82.00
-2.29
-23.00
153.00
-30.00
growth rate 0.0% 100.0% -100.0% 0.0% 100.0% 49.1% -100.0% 0.0% 100.0% -100.0%
Income Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 178.60
234.80
286.20
273.38
281.89
312.75
404.47
489.33
488.80
560.90
782.40
growth rate 31.5% 21.9% -4.5% 3.1% 11.0% 29.3% 21.0% -0.1% 14.8% 39.5%
Op.Income 29.90
40.20
73.60
23.02
23.52
31.14
89.19
151.34
105.50
124.30
110.60
growth rate 34.5% 83.1% -68.7% 2.2% 32.4% 186.5% 69.7% -30.3% 17.8% -11.0%
IBT 32.00
41.50
73.40
31.94
32.07
43.37
84.19
135.72
99.20
118.60
81.50
growth rate 29.7% 76.9% -56.5% 0.4% 35.3% 94.1% 61.2% -26.9% 19.6% -31.3%
Net Income 20.70
31.10
51.70
23.02
23.52
31.14
36.74
62.87
51.80
82.60
62.70
growth rate 50.2% 66.2% -55.5% 2.2% 32.4% 18.0% 71.1% -17.6% 59.5% -24.1%
EPS 0.68
0.99
1.59
0.64
0.65
0.85
0.88
1.41
1.13
1.71
1.22
growth rate 45.6% 60.6% -59.8% 1.6% 30.8% 3.5% 60.2% -19.9% 51.3% -28.7%
Gross Profit 144.50
188.50
239.10
231.21
235.81
250.62
197.78
272.49
255.60
275.80
317.30
growth rate 30.5% 26.8% -3.3% 2.0% 6.3% -21.1% 37.8% -6.2% 7.9% 15.1%
R&D 59.50
74.60
89.30
124.83
120.23
119.93
104.72
142.80
142.80
142.80
142.80
growth rate 25.4% 19.7% 39.8% -3.7% -0.2% -12.7% 36.4% 0.0% 0.0% 0.0%

Quarterly Statements

Item Name Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Earnings BIT 67.48
21.51
30.08
-27.20
-7.00
growth rate -68.1% 39.9% -100.0% 0.0%
Balance Sheet Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Acct.Receivable 189.49
76.96
271.10
121.50
218.10
growth rate -59.4% 252.3% -55.2% 79.5%
Acct.Payable 41.63
38.87
80.70
78.60
124.50
growth rate -6.6% 107.6% -2.6% 58.4%
Cur.Assets 541.31
563.15
620.80
528.50
692.70
growth rate 4.0% 10.2% -14.9% 31.1%
Total Assets 1,138.89
1,173.62
2,229.40
2,153.70
2,321.30
growth rate 3.1% 90.0% -3.4% 7.8%
Cash 190.24
339.36
112.20
137.20
177.40
growth rate 78.4% -66.9% 22.3% 29.3%
Inventory 139.37
125.75
205.80
211.00
232.00
growth rate -9.8% 63.7% 2.5% 10.0%
Cur.Liabilities 96.81
102.01
200.40
248.40
301.20
growth rate 5.4% 96.4% 24.0% 21.3%
Liabilities 200.55
206.97
1,218.50
1,166.20
1,332.40
growth rate 3.2% 488.7% -4.3% 14.3%
LT Debt 13.48
13.50
784.50
732.40
832.00
growth rate 0.1% 5,713.3% -6.6% 13.6%
Equity 938.35
966.65
1,010.90
987.50
988.90
growth rate 3.0% 4.6% -2.3% 0.1%
Common Shares 0.05
0.05
0.10
0.10
0.10
growth rate 0.0% 96.1% 0.0% 0.0%
Cash Flow Statement Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Capital Expenditures 13.60
26.06
20.83
21.40
14.10
growth rate 91.6% -20.1% 2.8% -34.1%
Cash Dividends
growth rate
Cash From OA 34.58
173.97
-165.76
104.80
-35.80
growth rate 403.1% -100.0% 100.0% -100.0%
Sale Purchase of Stock 3.77
growth rate
FCF 20.98
147.92
-186.59
83.40
-49.90
growth rate 605.0% -100.0% 100.0% -100.0%
Income Statement Jun '18 Sep '18 Dec '18 Mar '19 Jun '19
Sales 220.20
173.65
270.73
190.60
243.20
growth rate -21.1% 55.9% -29.6% 27.6%
Op.Income 67.48
21.51
30.08
-27.20
-7.00
growth rate -68.1% 39.9% -100.0% 0.0%
IBT 65.82
21.56
3.54
-37.80
-15.10
growth rate -67.3% -83.6% -100.0% 0.0%
Net Income 50.14
20.95
-3.48
-26.00
-9.50
growth rate -58.2% -100.0% 0.0% 0.0%
EPS
growth rate
Gross Profit 106.98
63.62
114.97
52.70
78.50
growth rate -40.5% 80.7% -54.2% 49.0%
R&D 52.00
52.00
52.00
63.90
63.90
growth rate 0.0% 0.0% 22.9% 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

D (39.71)

YOY Growth Grade:

D (47.25)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 59.21 54.43 14.01
EPS / Growth 4.0% 0.80 22.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 16.5%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 4.0% 14.2% 14.2%
Future PE 8.02 33.85 33.85
Future EPS 1.19 3.02 3.02
Value Price
MOS %
2.36
-94.6%
25.25
-42.1%
25.25
-42.1%
MOS Price 1.18 12.63 12.63
IRT 28.76 15.44 15.44

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.